Premis (Càtedra UB-Dr Antoni Esteve i Subirana de Recerca en Farmacologia)

URI permanent per a aquesta col·leccióhttps://hdl.handle.net/2445/228678

 Estadístiques

Examinar

Enviaments recents

Mostrant 1 - 3 de 3
  • Miniatura
    logoOpenAccessInforme
    The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease
    (Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia , 2025-10) Badia Fernàndez, Pau
    Alzheimer’s disease is a severe neurodegenerative disorder that affects approximately 5% of the European population, a percentage that increases substantially among the elderly. It is also the leading cause of dementia in older adults, accounting for more than 60% of cases. Moreover, it affects not only the individual suffering from the disease but also the patient’s environment—family, friends, and acquaintances—resulting in a significant economic burden. For these reasons, Alzheimer’s disease represents a major public health issue, which becomes even more evident considering the ageing of the population.
  • Miniatura
    logoOpenAccessInforme
    Cocrystal Screening of a Nutraceutical Compound in the Context of Healthy Ageing
    (Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia, 2025-10) Sans Claro, Ariadna
    As science, technology, and medicine advance, human lifespan increases, leading society to face new ageing-related challenges and to pay greater attention to preventive care and overall well-being. Nutraceuticals have emerged as an option for those looking for health support backed by scientific evidence, rather than relying on dietary supplements or pseudo-scientific methods. In this project we aim to obtain a cocrystal: a homogeneous solid containing an Active Pharmaceutical Ingredient (API) and a second solid named conformer held together by weak interactions. The studied API is a food-derived compound known for its anti-inflammatory, antioxidant, and neuroprotective properties
  • Miniatura
    logoOpenAccessInforme
    Light-Controlled Modulation of Muscarinic Acetylcholine Receptors Using a Novel Subtype-Selective Photoswitchable Ligand
    (Universitat de Barcelona. Càtedra Dr. Antoni Esteve i Subirana de Recerca en Farmacologia, 2025-10) Torroja Soto, Xènia
    Traditional pharmacology presents several limitations; particularly, the lack of selectivity at the site of action, leading to unwanted toxic systemic effects. However, in recent years, photopharmacology has emerged as a complementary approach to solve the long-standing issue of off-target toxicity outside the disease location. By designing drugs whose activity can be regulated by light, this strategy enables both selective and reversible modulation of both drug activation (where needed) and inactivation (where potentially toxic). Nonetheless, this research aims at further advancing the development of light-controllable pharmacological tools, improving the safety and efficacy of current treatments.